Literature DB >> 32929394

Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.

Antoine Leuzy1, Kerstin Heurling2, Susan De Santi3, Santiago Bullich3, Oskar Hansson1,4, Johan Lilja1,5,6.   

Abstract

Quantification may help in the context of amyloid-β positron emission tomography (PET). Quantification typically requires that PET images be spatially normalized, a process that can be subject to bias. We herein aimed to test whether a principal component approach (PCA) previously applied to [18F]flutemetamol PET extends to [18F]florbetaben. PCA was applied to [18F]florbetaben PET data for 132 subjects (70 Alzheimer dementia, 62 controls) and used to generate an adaptive synthetic template. Spatial normalization of [18F]florbetaben data using this approach was compared to that achieved using SPM12's magnetic resonance (MR) imaging driven algorithm. The two registration methods showed high agreement and minimal difference in standardized uptake value ratios (SUVR) (R2 = 0.997 using cerebellum as reference region and 0.996 using the pons). Our method allows for robust and accurate registration of [18F]florbetaben images to template space, without the need for an MR image, and may prove of value in clinical and research settings. AJNMMI
Copyright © 2020.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β; PET; [18F]florbetaben; adaptive template

Year:  2020        PMID: 32929394      PMCID: PMC7486549     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  28 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

Review 3.  The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Authors:  Mark E Schmidt; Ping Chiao; Gregory Klein; Dawn Matthews; Lennart Thurfjell; Patricia E Cole; Richard Margolin; Susan Landau; Norman L Foster; N Scott Mason; Susan De Santi; Joyce Suhy; Robert A Koeppe; William Jagust
Journal:  Alzheimers Dement       Date:  2014-11-24       Impact factor: 21.566

4.  Yes we can analyse amyloid images - Now What?

Authors:  Henryk Barthel; John Seibyl; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05       Impact factor: 9.236

5.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Authors:  Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer
Journal:  Alzheimers Dement       Date:  2015-03-28       Impact factor: 21.566

6.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

Review 7.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

Review 8.  Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.

Authors:  Kerstin Heurling; Antoine Leuzy; Eduardo R Zimmer; Mark Lubberink; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-06       Impact factor: 9.236

9.  Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.

Authors:  S M Landau; B A Thomas; L Thurfjell; M Schmidt; R Margolin; M Mintun; M Pontecorvo; S L Baker; W J Jagust
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-20       Impact factor: 9.236

10.  A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease.

Authors:  Enrico R Fantoni; Anastasia Chalkidou; John T O' Brien; Gill Farrar; Alexander Hammers
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more
  2 in total

Review 1.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 2.  Quantification of amyloid PET for future clinical use: a state-of-the-art review.

Authors:  Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.